clinical trial · NCT04484025
SPI-1005 Treatment in Moderate COVID-19 Patients
Sound Pharmaceuticals, Incorporated·phase2·unknown·n = 60
Covid19Corona Virus InfectionCoronavirusCoronavirus InfectionEbselenPlacebo
brief summary
The study is a randomized, double-blind, placebo-controlled, dose escalation, multi-center clinical trial (RCT) of SPI-1005 in adult subjects with positive PCR test for novel SARS-CoV-2 (nCoV2) and moderate symptoms of COVID-19 disease.
started
Oct 12, 2021
primary completion
Dec 31, 2023
completion
Dec 31, 2023
last updated
Oct 3, 2023
official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Moderate COVID-19 Patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol